GSK will use promising results from two studies of its experimental chronic hepatitis B therapy to support planned regulatory ...

GSK will be filing for approval of bepirovirsen in hepatitis B to global regulatory authorities based on the Phase III data.

Hepatitis B is a virus that can damage the liver and lead to lifelong health problems. The hepatitis B vaccine prevents short ...

The U.S. is cutting the Hepatitis B vaccine from its recommended list. But here's a place where the medical establishment — ...

The change follows a controversial recommendation from the CDC's Advisory Committee on Immunization Practices (ACIP) to no ...

GSK's experimental drug to treat chronic hepatitis B infection met the main goal in two closely watched studies, the ...

GSK’s potential “functional cure” for hepatitis B drug has proven its worth in a pair of hotly anticipated phase 3 studies, setting up the pharma for a push to the FDA.

Topline data were announced from two phase 3 studies evaluating bepirovirsen for the treatment of chronic hepatitis B.

The companies didn’t provide details, but said global regulatory filings are now planned for the therapy, an oligonucleotide meant to provide “functional cures” for chronic hepatitis B infections.

CDC recommendations have been altered for another vaccine, to the confusion of vaccination experts. The Observer has answers ...

Though specific data for bepirovirsen remain under wraps, GSK plans to file for approval in the first quarter of 2026.

The FDA designated the recall of certain Medtronic Bravo esophageal pH monitoring capsules as class I, the most serious type.